Catalyst Pharmaceutical Partners Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

19 Dec 2014
Price Change (% chg)

$0.04 (+1.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CPRX.O


Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011,... (more)


Beta: 0.79
Market Cap (Mil.): $204.59
Shares Outstanding (Mil.): 69.12
Dividend: --
Yield (%): --


  CPRX.O Industry Sector
P/E (TTM): -- 159.35 38.84
EPS (TTM): -0.22 -- --
ROI: -40.78 -0.82 18.26
ROE: -45.53 -1.98 19.12
Search Stocks

UPDATE 1-Catalyst Pharma's lead drug succeeds in late-stage study

Sept 29 - Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated with a rare autoimmune disorder, compared with a placebo.

29 Sep 2014

BRIEF-Catalyst Pharmaceuticals announces positive top-line PHASE 3 data from Firdapse clinical trial

* Announces positive top-line PHASE 3 data from Firdapse clinical trial in patients with lambert-eaton myasthenic syndrome

29 Sep 2014


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks